We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
QIAGEN Acquires ESE GmbH
News

QIAGEN Acquires ESE GmbH

QIAGEN Acquires ESE GmbH
News

QIAGEN Acquires ESE GmbH

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "QIAGEN Acquires ESE GmbH"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

QIAGEN N.V. has announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

ESE has pioneered the development and manufacturing of optical measurement systems for medical and industrial applications. The systems utilize high-performance fluorescence detection technologies integrated into compact modules.

ESE’s solutions are considered as an emerging standard for the detection of fluorescent signals in a wide range of molecular testing applications, most notably in nucleic acid-based point-of-need testing. In addition to portable solutions for point-of-need testing, these miniaturized, low-cost fluorescence detection modules can be integrated in laboratory instruments as well.

The systems’ “ultra-fast time to result” and high portability open new opportunities in healthcare and applied testing, enabling low-throughput molecular testing in practices, emergency rooms, remote field areas, and other settings where a laboratory infrastructure is not accessible and fast turnaround is required.

ESE’s fluorescence detection systems can be battery operated, process up to eight samples at a time and even permit testing of samples for several parameters in a single run (multiplex testing). As the proprietary technology allows for the detection modules to be manufactured at very low cost, the complete solutions can sell for less than US$2,000 per unit.

QIAGEN has demonstrated that ESE’s fluorescence detection systems can be used to measure signals generated by the Company’s existing testing technologies, including the HDA and tHDA isothermal assay systems, which QIAGEN has licensed from BioHelix in 2008. These isothermal assay technologies are an integral part of QIAGEN’s next generation screening platform QIAensemble. Therefore, assay development for the fluorescence detection systems can benefit from ongoing research activities for the QIAensemble platform.

QIAGEN has verified the ability of ESE’s systems to run HDA-based assays for several pathogens including Salmonella and E.colibacteria as well as Influenza viruses. Analysis can be performed directly on samples or following an upfront sample preparation step integrated into the devices using QIAGEN’s sample technologies.
Advertisement